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Objectives: This systematic review and meta-analysis was conducted to estimate the effects
of intravenous and nebulized magnesium sulfate on treating adults and children with acute
asthma.
Methods: Electronic literature search and themanual search of key respiratory journals were per-
formed up to October 18, 2011. Randomized controlled trials were included if patients had been
treatedwith intravenous or nebulizedmagnesium sulfate in combinationwith b2-agonists andwere
compared with the use of b2-agonists. Standardizedmean differences (SMDs) and the relative risks
(RRs) were calculated for pulmonary functions and hospital admission respectively.
Results: 25 trials (16 intravenous, 9 nebulized) involving 1754 patients were included. In adults
intravenous treatment was associated with a significant effect upon respiratory functiont of Nutrition and Food Hygiene and Ministry of Education Key Lab of Environment and Health,
l College, Huazhong University of Science and Technology, 13 Hangkong Road, Wuhan 430030, China.
.com (J. Xie), lgliu@mails.tjmu.edu.cn (L. Liu).
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322 Z. Shan et al.(SMD, 0.30; 95% confidence interval (CI), 0.05 to 0.55; pZ 0.02) but weak evidence of effect upon
hospital admission (RR 0.86,95% CI 0.73 to 1.01; pZ 0.06) in adults, and in children with significant
effects upon both respiratory function (SMD, 1.94; 95% CI, 0.80 to 3.08; pZ 0.0008) and hospital
admission (RR, 0.70; 95% CI, 0.54 to 0.91; pZ 0.008). Nebulized treatment was associated with
significanteffectsuponrespiratory function (SMD, 0.23; 95%CI, 0.06 to0.41;pZ0.009)andhospital
admission (RR, 0.63; 95% CI, 0.43 to 0.92; pZ 0.02) in adults.
Conclusion: The use of intravenous magnesium sulfate, in addition to b2-agonists and systemic
steroids, in the treatment of acute asthma appears to produce benefits with respect to improve
pulmonary function and reduce the number of hospital admissions for children, and only improve
pulmonary function for adults. However, the use of nebulized magnesium sulfate just appears to
produce benefits for adults.
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Multicentre studies conducted in large general populations
indicate that asthma is a disease extremely prevalent with
up to 1 out of 10 adults and 1 out of 3 children worldwide.1
During the past ten years, the prevalence of asthma,
especially in children, appears an obviously ascendant
trend, causing a significant personal and social burden.
However, the control of asthma remains poorly conducted
in general population.
Standard treatment for asthma crisis includes short-
acting bronchodilator (SAB), b2-agonists, inhaled anticho-
linergic agents and corticosteroids, in addition to general
managements.2 However, there are still patients with
moderate to severe acute asthmatic attacks that may have
insufficient improvement, leading to hospital admission,
severe morbidity and even mortality. Numbers of studies
suggest magnesium sulfate as an additional treatment
option in patients resistant to standard therapy. In smooth
muscle, magnesium decreases intracellular calcium by
blocking its entry and its release from the endoplasmic
reticulum and activating sodiumecalcium pumps. Further-
more, inhibition of the interaction between calcium
and myosin results in muscle cell relaxation. Magnesium
also stabilizes T cells and inhibits mast cell degranulation,leading to a reduction in inflammatory mediators. In
cholinergic motor nerve terminals, magnesium depresses
muscle fiber excitability by inhibiting acetylcholine release.
Lastly, magnesium stimulates nitric oxide and prostacyclin
synthesis, which might reduce asthma severity.3,4
In some countries intravenousmagnesium sulfate is widely
used for acute asthma, usually for patients with severe or
life-threatening asthma who have not responded to initial
treatments. For example, the most recent revised (2012)
BTS/SIGN guidelines state that a single dose of intravenous
magnesium sulfate has been shown to be safe and effective in
adults, and should be considered in adults with life threat-
ening features or acute severe asthma that has not responded
to inhaled bronchodilator treatment. The guidelines for
children are more equivocal, suggesting that intravenous
magnesium sulfate is safe but its place in management is
not yet established.5 In addition, in the UK intravenous
magnesium sulfate is used in the treatment of acute asthma
in over 90% of adult emergency departments, usually for
patients with severe or life-threatening asthma who have
not responded to initial treatments in 2009.6 However, in the
BTS/SIGN guidelines, they do not mention nebulized magne-
sium sulfate.5 And in the UK, nebulized magnesium sulfate
is hardly used at all, with most emergency practitioners
feeling that there was insufficient evidence to justify its use.6
Intravenous and nebulized magnesium sulfate for treating acute asthma 323We therefore aimed to undertake a systematic review
and meta-analysis of both intravenous and nebulized
magnesium sulfate to determine their roles in adults and
children with acute asthma.
Methods and materials
Selection criteria and identification of studies
We planned to identify all randomized or quasi-randomized
trials of intravenous or nebulized magnesium sulfate as an
adjuvant in combination with b2-agonists in adults or chil-
dren with acute asthma, which reported a measure of
pulmonary function or hospital admission as an outcome.
Age restriction was considered for patients included in
the studies and the participants were categorized into two
groups: 2e16 years old (the children group) and 16
years old (the adults group). This study included studies
comparing magnesium sulfate & b2-agonists with
b2-agonists & placebo, but excluded those comparing
magnesium sulfate with b2-agonists.
Two investigators searched electronic databases
including PubMed/MEDLINE, EMBASE, CENTRAL, CINAHL
databases and manually searched key respiratory journalsTotal number of poten
identified in data
N=1
Children 
N=5 
Adults
N=11 
Total number of intravenous 
trails included in the review 
N=16 
Total number of 
invention group and 
 N=
Total number of RCTs
N=
One trial excluded for o
Figure 1 Flow chart showing the selection of trialsup to October 18, 2011. The PubMed search strategy was as
follows: ((magnesium) AND (asthma)) AND ((randomized
controlled trial) OR (quasi-randomized controlled trial)).
Similar search terms were used for EMBASE and other
databases. In addition, references of relevant original
papers and review articles were screened.
Quality assessment
The quality of each included study was assessed using the
five point Jadad score.4,7e30 This scale is used to assess
randomization, double blinding and withdrawals/dropouts.
All trials were scored using a scale of 1e5 (score of 5 being
the highest).
Data extraction
Data extraction was carried out independently by two
authors using a unanimous extraction form. To resolve
discrepancies, group consensus and consulting with a third
reviewer were employed. The following data were extrac-
ted: title, authors, year of publication, participants (sample
size, age, gender, severity of asthma); interventions (route
of administration, dose, timing and duration of therapy,tially relevant articles 
base search  
66 
Adults
N=8 
Children 
N=1 
Total number of nebulised 
trails included in the review 
N=9 
articles including 
control group  
50 
 suitable for inclusion 
26 
utcomes not applicable 
in the review. RCTs, randomized controlled trials.
Table 1 Characteristics of studies of intravenous magnesium sulfate.
Study Location Publication
year
Sample
size
Age
range
Sex %F:M Asthma severity Jadad
score
Outcome measures used
Singh India 2008 60 18e60 52:48 Severe 5 FEV1 (% predicted) and admissions
Bijani Iran 2002 81 12e85 47:53 Severe 3 PEFR
Silverman USA 2002 248 18e60 42:58 Severe 5 PEFR and admissions
Porter USA 2001 42 18e55 64:36 Moderateesevere 5 PEFR and admissions
Bilaceroglu Turkey 2001 81 16e65 69:31 Moderateesevere 2 FEV1 (% predicted) and admissions
Boonyavorakul Thailand 2000 33 15e65 88:12 Severe 5 Admissions
Scarfone USA 2000 54 1e18 48:52 Moderateesevere 5 Admissions
Ciarallo USA 2000 30 6e18 40:60 Moderateesevere 4 PEFR (change in % predicted)
and admissions
Gurkan Turkey 1999 20 6e16 55:45 Moderateesevere 3 PEFR (% change from baseline)
Devi India 1997 47 1e12 23:77 Severe 4 PEFR (% predicted)
Ciarallo USA 1996 31 6e18 55:45 Moderateesevere 4 PEFR (% change from baseline)
and admissions
Bloch USA 1995 135 18e65 72:28 Moderateesevere 5 FEV1 (% predicted)
and admissions
Matusiewicz UK 1994 129 >16 57:42 Moderateelife
threatening
5 PEFR and admissions
Tiffany USA 1993 48 18e60 59:41 Severe 4 PEFR
Green USA 1992 120 18e65 77:23 Acute exacerbation 1 PEFR and admissions
Skobeloff USA 1989 38 18e70 74:26 Moderateesevere 5 PEFR and admissions
FEV1, forced expiratory volume in 1 s; PEFR, peak expiratory flow rate.
324 Z. Shan et al.co-interventions); control (agents and doses used); outcomes
(types of outcome measures and hospital admission rates)
and results. In some early publications with missing data,
we collected the data from a previous meta-analysis.31Statistical analysis
We computed standardized mean differences (SMDs) for
pulmonary functions and the relative risks (RRs) for
hospital admission. The Cochran Q test and the I2 statistic
were employed to estimate the heterogeneity betweenTable 2 Characteristics of studies of nebulized magnesium sulf
Study Location Publication
year
Sample
size
Age
range
S
Allegos-Solo´rzano Mexico 2010 60 >18 7
Aggarwal India 2006 100 13e60 4
Drobina USA 2006 110 12e60 4
Kokturk Turkey 2005 26 18e60 7
Mahajan USA 2004 62 5e17 4
Hughes New Zealand 2003 52 16e65 5
Bessmertny USA 2002 74 18e65 7
Changqiong Xu China 2002 50 20e66 4
Nannini Argentina 2000 35 >18 6
FEV1, forced expiratory volume in 1 s; PEFR, peak expiratory flow ratstudies.32 Heterogeneity was confirmed with a significance
level of P < 0.10. I2 statistic describes the percentage
of total variation in point estimates that can be attributed
to heterogeneity.33 Fixed-effect model (ManteleHaenszel
method) was used when heterogeneity was negligible and
random-effect model (DerSimonian and Laird method)
was used when heterogeneity was significantly present.34
Forest plot and funnel plot were used to observe the
overall effect and assess the publication bias, respec-
tively. Sensitivity analyses were used to evaluate the
influence of each study by omitting one study at one time.
All tests were 2-sided with a significance level of 0.05.ate.
ex %F:M Asthma severity Jadad
score
Outcome
measures used
0:30 Severe 5 FEV1 (%predicted)and
admissions
0:60 Severe or life
threatening
5 PEFR and admissions
3:67 Mildesevere 5 PEFR and admissions
3:27 Moderateesevere 2 PEFR (%predicted)
and admissions
5:55 Mildemoderate 4 FEV1 (%predicted)
and admissions
2:48 Severeelife
threatening
5 FEV1 and admissions
3:27 Mildemoderate 5 FEV1 (%predicted)
6:54 Acute exacerbation FEV1 (%predicted)
3:37 Acute exacerbation 3 PEFR and admissions
e.
Table 3 Treatment regimens and co-interventions used in studies of intravenous magnesium sulfate.
Study Magnesium regimen Control regimen b-agonist regimen Corticosteroid regimen Co-interventions
Singh 2 g loading dose over 20 min 250 ml saline solution. Salbutamol 2.5 mg 0, 20,
40 min
100 mg IV hyd ocortisone Ipratropium
Bijani 25 mg/kg over 30e45 min 100 ml saline solution Salbutamol (interval not
stated)
Corticosteroid (type not stated) Aminophylline
Silverman 2 g loading dose over
10e15 min
50 ml saline solution Albuterol 0, 30, 60, 120,
180 min
125 mg IV MP None stated
Porter 2 g loading dose over 20 min 50 ml saline solution Albuterol 20 min
intervals
125 mg IV MP None stated
Bilaceroglu 2 g loading dose 100 ml of 5% dextrose Salbutamol 0, 30, 60,
120,180 min
125 mg MP if EFR,40%predicted Theophylline
Boonyavorakul 2 g loading dose 2 ml sterile water
in 50 ml saline
Salbutamol 0, 20, 40,
60 min
5 mg IV dexamethasone None stated
Scarfone 75 mg/kg over 20 min
(max 2.5 g)
Saline solution Albuterol 0.15 mg/kg 0,
40, 80, 120 min
1.0 mg/kg MP IV (max 125 mg) None stated
Ciarallo 40 mg/kg over 20 min (max 2 g) 100 ml saline solution Albuterol 2 mg/kg MP I (max 100 mg) Ipratropium
Gurkan 40 mg/kg over 20 min (max 2 g) Saline solution
equivalent volume
Salbutamol 0.15 mg/kg 2 mg/kg MP I (max 100 mg) None stated
Devi 100 mg/kg over 35 min Saline solution
equivalent volume
Salbutamol 0.15 mg/kg Hydrocortison IV/oral
(no dose prov ed)
Aminophylline
Ciarallo 25 mg/kg over 20 min (max 2 g) Saline solution
equivalent volume
Albuterol 0.15 mg/kg 2 mg/kg IV M None stated
Bloch 2 g loading dose over 20 min 50 ml saline solution Albuterol 0, 30, 60, 120,
180 min
125 mg IV MP f initial FEV1 40%
or oral steroid within last
6 months
Theophylline
Matusiewicz 1.2 g loading dose over 15 min 50 ml saline solution Salbutamol at discretion
of physician
200 mg IV hyd ocortisone Ipratropium neb,
aminophylline IV
Tiffany 2 g loading dose over 20 min
followed by infusion of MgSO4
or placebo
Saline solution Albuterol 30 min
intervals
125 mg IV MP Aminophylline
Green 2 g loading dose over 20 min No placebo Albuterol initially then
hourly
125 mg IV MP Theophylline bagonist
injection ephedrine
Skobeloff 1.2 g loading dose over 20 min 50 ml saline solution Metaproterol/Albuterol
at physician discretion
125 mg IV MP Theophylline IV
FEV1, forced expiratory volume in 1 s; IV, intravenous; MP, methylprednisolone; PEFR, peak expiratory flow rate.
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326 Z. Shan et al.RevMan software (version 5.1) was used for all statistical
analyses.
Results
Characteristics of the included studies
After reviewed by two independent reviewers, our searches
generated 194 reports prior to October 18, 2011, of which
25 studies (16 intravenous, 9 nebulized)4,7e30 met the
inclusion criteria. The flow of identified studies through the
selection process is shown in Fig. 1. Tables 1 and 2 showed
the characteristics of the 16 identified studies of intrave-
nous magnesium sulfate and 9 identified studies of nebu-
lized magnesium sulfate, respectively, for treating acute
asthma. Tables 3 and 4 showed the interventions and
co-interventions used in each study.
Intravenous magnesium sulfate in acute asthma
For intravenous magnesium sulfate, 16 studies (12 adults, 4
children) were included for the analyses of the effects of
intravenous magnesium sulfate upon respiratory function
and hospital admission in acute asthma (Table 1). In all
studies patients were treated with b2-agonists and systemic
steroids together. SMDs for pulmonary functions and RRs for
hospital admission were pooled using random-effect model
and fixed-effect model, respectively, according to results
from heterogeneity tests. In adults, intravenous magnesium
sulfate treatment is associated with a significant effect
upon respiratory function (SMD, 0.30; 95% CI, 0.05 to 0.55;
p Z 0.02), but weak evidence of effect upon hospital
admission (RR, 0.86; 95% CI, 0.73 to 1.01; pZ 0.06) (Fig. 2).
In children, intravenous magnesium sulfate treatment is
associated with significant effects upon respiratory func-
tion (SMD, 1.94; 95% CI, 0.80 to 3.08; p Z 0.0008) and
hospital admission (RR, 0.70; 95% CI, 0.54 to 0.91;
p Z 0.008) (Fig. 3). Funnel plot analyses were employed
and no publication bias was found in the included
studies (Supplementary Figs. 1 and 2). In addition, the final
conclusion of both adults and children groups never
changed in the sensitivity analyses by omitting one study at
one time.
Nebulized magnesium sulfate in acute asthma
For nebulized magnesium sulfate, 9 studies (8 adults, 1
children) were included for the analyses of the effects of
nebulized magnesium sulfate upon respiratory function and
hospital admission in acute asthma (Table 2). In most
studies except two15,21 patients were treated b2-agonists
and systemic steroids together. Fixed-effect model was
applied for SMRs for pulmonary functions and RRs for
hospital admission because the test for heterogeneity was
not significant. In adults, nebulized treatment is associated
with significant effects upon respiratory function (SMD,
0.23; 95% CI, 0.06 to 0.41; p Z 0.009) and hospital admis-
sion (RR, 0.63; 95% CI, 0.43 to 0.92; p Z 0.02) (Fig. 4).
However, in children there is only one study included and
shows no significant effect upon respiratory function
Figure 2 Effect of intravenous magnesium sulfate upon respiratory function.
Intravenous and nebulized magnesium sulfate for treating acute asthma 327(SMD, 0.36; 95% CI, 0.14 to 0.86; p Z 0.16) or hospital
admission (RR, 2.0, 95% CI, 0.19 to 20.93; pZ 0.56) (Fig. 5).
Funnel plot analyses were employed and no publication bias
was found in the included studies (Supplementary Figs. 3
and 4). By omitting two studies in which patients were
not treated with systemic steroids, the conclusion never
changed. In the adults group the final conclusion never
changed in the sensitivity analysis by omitting one study at
one time, while there was no sensitivity analysis in the
children group for there was only one study included.Figure 3 Effect of intravenous magnesDiscussion
This systematic review and meta-analysis attempted to
synthesize the most comprehensive review to date of the
role of magnesium sulfate in acute asthma. It provided
a systematic assessment of the effects of intravenous
and nebulized magnesium sulfate on treating adults and
children with acute asthma after reviewing 25 articles
(16 intravenous, 585 treatments and 600 controls; 9 nebu-
lized, 294 treatments and 275 controls).ium sulfate upon hospital admission.
Figure 4 Effect of nebulized magnesium sulfate upon respiratory function.
328 Z. Shan et al.There appeared to be a significant difference in effec-
tiveness between adults and children, so our meta-analysis
analyzed the articles for adults and children separately.
One possible explanation might be the difference of
susceptibility of their smooth muscle to magnesium sulfate
or the different doses used.
For intravenous magnesium sulfate, our results sug-
gested that treatment in addition to b2-agonists and
systemic steroids produced benefits with respect to
improved pulmonary function in both adults and children,
and reduced the number of hospital admissions by 30% in
children. Moreover, it might reduce the number of hospital
admissions in adults (p Z 0.06). For nebulized magnesium
sulfate, our results suggested that treatment in addition
to b2-agonists and systemic steroids was associated with
improved pulmonary function and reduced the number of
hospital admissions by 37% in adults. There was only one
trial in children included and it suggested that there was no
significant effect of nebulized magnesium sulfate upon
respiratory function or hospital admission. However, it wasFigure 5 Effect of nebulized magnesinot considered to be sufficient to judge the effect of
nebulized magnesium sulfate for children patients.
Our results were inconsistent to a previous meta-analysis
by Mohammed S,31 which just showed intravenous magne-
sium sulfate appeared to be an effective treatment in
children. Several factors might contribute to the difference.
First, we included three articles8e10 (2 intravenous inter-
vention with 92 treatments and 97 controls; 1 nebulized
intervention with 30 treatments and 30 controls) after
2006. Meanwhile, we included one article17 (intravenous
intervention with 25 treatments and 25 controls) excluded
by Mohammed S because it was only in Chinese. Second, two
studies35,36 were excluded in our analysis where magnesium
alone was compared directly with a b2-agonist (salbutamol),
which was more reasonable.
There are several potential limitations in this meta-
analysis. Firstly, the sample sizes in the included studies
were rather small, for example, no study includedmore than
150 treatments and 150 controls, which brought us to
undertake this meta-analysis to reach higher statisticalum sulfate upon hospital admission.
Intravenous and nebulized magnesium sulfate for treating acute asthma 329power. In addition, we calculated the weights of studies
according to their sample sizes. Secondly, there was a possi-
bility of study selection bias. However, two independent
reviewers felt confident that the reasons for the inclusion
and exclusion of studies were consistent and appropriate.
Our search was comprehensive and has been updated, so it is
unlikely that there are any published trials that were missed.
Thirdly, there was a lack of consensus among researchers
regarding themost appropriate pulmonary function outcome
measure to report. Consequently, we computed standard-
ized mean differences (SMDs) for pulmonary functions to
avoid the influence of different outcomemeasures. Fourthly,
the included studies were not stratified by asthma severity
based on the consideration of preserving the study power, for
example, if we evaluated the effect of intravenous magne-
sium sulfate for acute severe asthma, there was only one
study included for children reflecting the effect on hospital
admission. However, it might still be a limitation. Finally, in
most studies, patients were not treated with ipratropium
which is currently a standard treatment for acute severe
asthma. This means that magnesium has not been widely
tested against what is considered as guideline based therapy.
The results might change with ipratropium usage, so further
studies in this respect should be warranted.
Our analysis implies that intravenous and nebulized
magnesium sulfate could be additional standard treatments
for children and adults respectively, especially for the
patients with acute asthma that has not responded to initial
treatments, while the roles of both intravenous magnesium
sulfate in adults and nebulized magnesium sulfate in chil-
dren require further investigation. Considering the low risk
of serious side effects from magnesium sulfate and readily
availableness it would seem reasonable to use intravenous
and nebulized magnesium sulfate to treat patients with life
threatening features. Further studies with larger sample
sizes, especially involving nebulized magnesium sulfate in
children, should be warranted. Meanwhile, large random-
ized controlled trials are required to compare nebulized
and intravenous magnesium sulfate with each other and
with placebo, in patients with acute asthma, to establish
the optimal dosage and the most effective route of
administration.Appendix A. Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.rmed.2012.12.001.Conflict of interest statement
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